ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.
 PMID: 9517942       1998       Antimicrobial agents and chemotherapy
Abstract: HIV-1 strains containing the L100I, K103N, V106A, E138K, Y181C, or Y188H mutations in their reverse transcriptase (RT) displayed reduced sensitivity to the compounds.


  Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
 PMID: 9685236       1998       Journal of medicinal chemistry
Abstract: The most potent compounds were further evaluated against a panel of clinically significant mutant RT enzymes (K103N, V106A, G190A, P236L) and in cytotoxicity and in vitro metabolism assays.


  Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.
 PMID: 9768622       1998       Journal of acquired immune deficiency syndromes and human retrovirology
Abstract: HIV-1 resistance to ATV was detected in 41% of patients and was most commonly associated with RT mutations K103N and Y181C.


  Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.
 PMID: 9835502       1998       Antimicrobial agents and chemotherapy
Abstract: The most common genotypic change was the K103N substitution.
Abstract: The range of phenotypic resistance in samples containing the K103N substitution could not be predicted from a genotypic analysis of known NNRTI resistance-associated mutations.


  HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
 PMID: 9052722       1997       Journal of acquired immune deficiency syndromes and human retrovirology
Abstract: After treatment with DLV and ddI alone, isolates from five of seven patients developed Y181C, four in combination with K103N.


  Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
 PMID: 9087499       1997       Antimicrobial agents and chemotherapy
Abstract: As a group, the UC compounds were found to be less active against viruses with the L100I, K103N, and Y181C amino acid changes in the RT and, upon in vitro selection, yielded resistant virus with the Y181C mutation in the RT.


  Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.
 PMID: 9405155       1997       Journal of molecular biology
Abstract: Determination of the rate constants for Nevirapine binding (kon) and dissociation (koff) for the mutant and wild-type enzymes showed that mutations L100I and V106A increased the koff values by 12 and 8.5-fold, respectively, without significantly affecting the kon, whereas mutation K103N decreased the kon 5-fold without increasing the koff.
Abstract: The kinetic parameters governing the inhibition by Nevirapine of the RNA-dependent DNA synthesis catalyzed by HIV-1 reverse transcriptase have been determined by steady-state kinetic analysis with the wild-type enzyme and with mutant reverse transcripta
Abstract: less sensitive) Y188L < V106A < L100I < K103N < wild-type.


  Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
 PMID: 8700148       1996       Molecular pharmacology
Abstract: They were also highly efficient (EC50 < or = 0.02 microgram/ml) in suppressing the replication of mutant virus strains that contained mutations in their reverse transcriptase that conferred resistance to other non-nucleoside reverse transcriptase inhibitors (i.e., Tyr181 to Cys, Lys103 to Asn, Val106 to Ala, and Leu100 to Ile).


  Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
 PMID: 8815692       1996       Advances in experimental medicine and biology
Abstract: The most common genotypic mutations seen to date are K103N and P236L.


  Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.
 PMID: 8896496       1996       The Journal of infectious diseases
Abstract: Accumulation of drug resistance mutations (mainly V75I, F77L, K103N, F116Y, Q151M, and M184V) eventually resulted in a strain that was genotypically and phenotypically resistant to all tested ddNs and the majority of NNRTIs.



Browser Board

 Co-occurred Entities




   Filtrator